Due to its immune regulatory function, triggering CD99 may act as an immunomodulator, boosting the activity of immune cells and possibly serving as an adjuvant alongside other tumor therapies when combined with anti-CD99 antibodies. This evidence concerns the gene CD99 and neoplasm.